Compared with oral formulations, transdermal and intranasal forms of postmenopausal HT produce smaller changes in levels of the cardiovascular risk markers. . .
Compared with oral formulations, transdermal and intranasal forms of postmenopausal hormone therapy (HT) produce substantially smaller changes, if any, in levels of the cardiovascular risk markers, C-reactive protein (CRP) and activated protein C (APCr), suggesting that they pose less of a threat of atherosclerotic and venous thromboembolic disease.
The finding comes from a systematic review of 72 randomized clinical trials. The authors of the review also noted that changes in cell adhesion molecules and some fibrinolytic parameters tended to be smaller with non-oral treatment than with oral HT, whereas changes in lipoprotein(a) and homocysteine did not differ between oral and non-oral forms of therapy. There were also minor or no differences between formulations in their effect on coagulation parameters.
Hemelaar M, van der Mooren MJ, Rad M, et al. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril. 2008;90:642-668.
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More